Carisma Therapeutics Inc (NASDAQ:CARM) has a beta value of 1.86 and has seen 1.33 million shares traded in the recent trading session. The company, currently valued at $18.02M, closed the recent trade at $0.43 per share which meant it gained $0.03 on the day or 7.75% during that session. The CARM stock price is -220.93% off its 52-week high price of $1.38 and 67.44% above the 52-week low of $0.14. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.7 million shares traded. The 3-month trading volume is 14.50 million shares.
The consensus among analysts is that Carisma Therapeutics Inc (CARM) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.09.
Carisma Therapeutics Inc (NASDAQ:CARM) trade information
Sporting 7.75% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CARM stock price touched $0.43 or saw a rise of 5.64%. Year-to-date, Carisma Therapeutics Inc shares have moved -62.52%, while the 5-day performance has seen it change 9.11%. Over the past 30 days, the shares of Carisma Therapeutics Inc (NASDAQ:CARM) have changed -28.55%. Short interest in the company has seen 3.1 million shares shorted with days to cover at 0.09.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 92.83% from the levels at last check today.. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -1295.35% off the targeted high while a plunge would see the stock gain -1295.35% from the levels at last check today..
Carisma Therapeutics Inc (CARM) estimates and forecasts
The company’s shares have lost -9.09% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -23.59%.
1 analysts offering their estimates for the company have set an average revenue estimate of 3.75M for the current quarter. 1 have an estimated revenue figure of 3.75M for the next ending quarter. Year-ago sales stood 9.2M and 3.38M respectively for this quarter and the next, and analysts expect sales will shrink by -59.23% for the current quarter and -23.59% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 42.71% over the past 5 years. Earnings growth for 2025 is a modest 71.92% while over the next 5 years, the company’s earnings are expected to increase by 27.78%.
CARM Dividends
Carisma Therapeutics Inc is expected to release its next earnings report on 2025-May-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Carisma Therapeutics Inc (NASDAQ:CARM)’s Major holders
Insiders own 27.76% of the company shares, while shares held by institutions stand at 31.76% with a share float percentage of 43.96%. Investors are also buoyed by the number of investors in a company, with Carisma Therapeutics Inc having a total of 44.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 1.45 million shares worth more than $2.2 million. As of 2024-06-30, VANGUARD GROUP INC held 3.4861% of shares outstanding.
The other major institutional holder is TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, with the holding of over 1.25 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.9 million and represent 3.014% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 2.50% shares in the company for having 1.05 shares of worth $0.44 million while later fund manager owns 342.63 shares of worth $0.15 million as of Mar 31, 2025 , which makes it owner of about 0.82% of company’s outstanding stock.
